Detection of HIV-1 resistant to antiretroviral drugs among tomsk oblast population with newly diagnosed HIV-infection

The purpose of this paper is to evaluate the spreading of HIV-1 resistant to antiretroviral drugs among Tomsk Oblast population with newly diagnosed HIV-infection.

Materials and methods. It was collected 122 clinical samples of  peripheral blood of HIV-infected patients from Tomsk Oblast who did not take antiretroviral drugs. In HIV-1 isolated from clinical samples we studied nucleotide sequence of genome fragments encoding virus protease and reverse transcriptase. Complex analyses of epidemiologic data from patients and the presence in genome HIV-1 mutations associated with resistance development to protease inhibitors and virus reverse transcriptase were carried out.

Results. Analysis of HIV-1 isolated from Tomsk Oblast naïve HIV-infected population made it possible to detect HIV-1 mutations associated with a decrease of virus sensitivity to antiretroviral drugs in 9,8% of cases. Among described mutations 50% were associated with resistance to virus protease inhibitors; 33,3% were resistance mutations to nonnuclease inhibitors of reverse transcriptase, and 16.7% were resistance mutations to nucleoside inhibitors of virus reverse transcriptase. Out of 9,8% of resistant viruses 7,3% of cases
included mutations associated with the development of potentially low level of reduction of HIV-1 sensitivity to drugs. Main HIV-1 resistance mutations of high and average levels were registered only in 2,5% of genotyped HIV-1 isolated from people who inject drugs.

Conclusion. Current study detected considerably low sampling rate of HIV-1 carrying mutations associated with resistance to antiretroviral drugs among Tomsk Oblast naïve HIV-infected population. It is believed to be caused by a relatively short period of extensive application of antiretroviral therapy in that territory. Analysis of epidemiologic data resulted in detection of factors negatively affecting prediction of further development of HIV-infection epidemic in the region including prevalence of risk behavior practice contributing to resistant HIV-1 transmission both among patients via heterosexual contacts and among people who inject drugs.

1. Joint United Nations Programme on HIV/AIDS. 90-90-90. An ambitious treatment target to help end the AIDS epidemic. Geneva, Switzerland. – 2017. – UNAIDS. https://www.unaids.org/en/resources/documents/2017/90-90-90

2. Viswanathan S, Justice A.C, Alexander G.C. et al. Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2015; 69(4): 493–498. DOI: 10.1097/QAI.0000000000000643; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482798/

3. Yang W.L., Kouyos R., Scherrer A.U. et al. Assessing the paradox between transmitted and acquired HIV type 1 drug resistance mutations in the Swiss HIV Cohort Study from 1998 to 2012. J Infect Dis. 2015; 212(1): 28–38. DOI: 10.1093/infdis/jiv012. Epub 2015 Jan 9; https://www.ncbi.nlm.nih.gov/pubmed/25576600

4. De Luca A., Dunn D., Zazzi M. et al. Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe. J Infect Dis. 2013; 207(8): 1216 – 1220. DOI: 10.1093/infdis/jit017. Epub 2013 Jan 11; https://www.ncbi.nlm.nih.gov/pubmed/23315324

5. Montaner J.S., Lima V.D., Harrigan P.R. et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV treatment as prevention” experience in a Canadian setting. PLoS One. 2014; DOI:10.1371/journal.pone.0087872; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0087872

6. Rhee S.Y., Blanco J.L., Jordan M.R. et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015; DOI: 10.1371/journal.pmed.1001810; https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001810

7. Pham Q.D., Wilson D.P., Law M.G. et. al. Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis. AIDS. 2014; 28(218): 2751–2762. DOI: 10.1097/QAD.0000000000000494; https://www.ncbi.nlm.nih.gov/pubmed/25493601

8. Hofstra L.M., Sauvageot N., Albert J. et al. Hofstra, L.M. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. Clin Infect Dis. 2016; 62(5): 655–663. DOI: 10.1093/cid/civ963; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4741360/

9. Manosuthi W., Tongyen S., Nilkamhang S. et al. HIV-1 drug resistance-associated mutations among antiretroviralnaive thai patients with chronic HIV-1 infection. J Med Virol. 2013; 85(2): 194–199. DOI: 10.1002/jmv.23452; https://www.ncbi.nlm.nih.gov/pubmed/23161095

10. Update on HIV-1 Strain and Transmitted Drug Resistance in Canada: Findings from the Canadian HIV Strain and Drug Resistance Surveillance Program, 2012-2013. Ottawa, Canada. 2017; https://www.canada.ca/content/dam/phac-аspc/documents/services/publications/diseases-conditions/hiv-canadian-strain-drug-resistance-surveillance-2012-2013/hiv-canadian-strain-drug-resistance-surveillance-2012-2013.pdf

11. Bennett D.E., Myatt M., Bertagnolio S. et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antiviral Ther. 2008; 13(2): 25–36. https://www.ncbi.nlm.nih.gov/pubmed/18575189

12. Sax P., Islam R., Walensky R. et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005; 41(9): 1316–1323. DOI: 10.1086/496984; https://academic.oup.com/cid/article/41/9/1316/278613

13. Wittkop L., Günthard H.F., F de Wolf et al. EuroCoordCHAIN study group. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011; 11(5): 363-371. DOI: 10.1016/S1473-3099(11)70032-9; https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70032-9/fulltext

14. Hall T.A. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser. 1999; 41: 95-98. http://brownlab.mbio.ncsu.edu/JWB/papers/1999Hall1.pdf

15. Tamura K., Stecher G., Peterson D. et al. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol. 2013; 30(12): 2725-2729. DOI: 10.1093/molbev/mst197; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840312/

16. Tang, M.W., Liu T.F., Shafer R.W. The HIVdb system for HIV-1 genotypic resistance interpretation. Intervirology. 2012; 55: 98–101. DOI: 10.1159/000331998; https://pdfs.semanticscholar.org/4766/154290625737287fc25888edfee35495c4fc.pdf

17. Bennett D.E., Camacho R.J., Otelea D. et al Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update. PLoS ONE 2009; DOI: 10.1371/journal.pone.0004724; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004724

18. Gashnikova, N.M. Molekulyarno-epidemiologicheskaya harakteristika rasprostraneniya VICH-infekcii na YUge Rossii. / N.M. Gashnikova [i dr.] // VICH-infekciya i immunosupressii. – 2013. – № 5(4). – S. 73–81.

19. Suhanova, A.L. Polimorfizm oblasti genoma, kodiruyushchej proteazu i obratnuyu transkriptazu, variantov VICH-1 podtipa A, rasprostranennyh na territorii SNG. / A.L. Suhanova [i dr.] // Molekulyarnaya biologiya. – 2005. – № 39(6). – S. 1063–1071.19. Tang M.W., Shafer R.W. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs. 2012; 72(9): e1–e25. DOI: 10.2165/11633630-000000000-00000; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689909/

20. Gashnikova N.M., Astakhova E.M., Gashnikova M.P. et al. HIV-1 Epidemiology, Genetic Diversity, and Primary Drug Resistance in the Tyumen Oblast, Russia. Biomed Res Int. 2016; DOI: 10.1155/2016/2496280; https://www.hindawi.com/journals/bmri/2016/2496280/

21. Lebedev, A.V. Cravnitel’nyj analiz geneticheskih variantov VICH-1, cirkulirovavshih v Irkutskoj oblasti v 1999 i 2012 gg. / A.V. Lebedev [i dr.] // Problemy virusologii. – 2016. – № 61(3). – С. 112-118. DOI: 10.18821/0507-4088-2016-61-3-112-118; https://cyberleninka.ru/article/n/sravnitelnyy-analizgeneticheskih-variantov-vich-1-tsirkulirovavshih-v-irkutskoyoblasti-v-1999-i-2012-gg

22. Kolomeets A.N., Varghese V., Lemey P. et.al. A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses. AIDS. 2014; 28(17): F1–F8. DOI: 10.1097/QAD.0000000000000485; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4393743/

23. Kolomeec, A.N. Epidemiologicheskie i molekulyarnogeneticheskie osobennosti VICH u inficirovannyh lic na territorii Sibirskogo federal›nogo okruga / A.N. Kolomeec [i dr.] // MediAl›. – 2016. – № 1(18): S. 16–20. https://www.medialjournal.ru/jour/article/view/3/4

24. Kazennova E.V., Laga V.Ye., Lapovok I.A. et al. HIV-1 genetic variants in the Russian far east. AIDS Research and Human Retroviruses. 2014; 30(8): 742–752. DOI: 10.1089/aid.2013.0194; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4118705/

25. Vázquez De Parga, Rakhmanova A., Pérez-Álvarez L. et al E. Analysis of drug resistance-associated mutations in treatment-naïve individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J Med Virol. 2005; 77(3): 337–344. DOI: 10.1002/jmv.20461; https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.20461

26. Gashnikova N.M., Zyryanova D.P., Astakhova E.M. et al. Predominance of CRF63 02A1 and multiple patterns of unique recombinant forms of CRF63 A1 among individuals with newly diagnosed HIV-1 infection in Kemerovo Oblast, Russia. Arch Virol. 2016; 162(2): 379-390. DOI: 10.1007/s00705-016-3120-4; https://link.springer.com/article/10.1007/s00705-016-3120-4